Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IMNM with free AI briefings, catalyst countdowns, and dilution alerts.

IMNM · Immunome Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$461.6M Cash on Hand
22.6mo Cash Runway
Follow IMNM by email Get an email when IMNM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IMNM, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoA
2027-04-28 varegacestat adults with desmoid tumors and assigned a PDUFA target actio NDA 63%

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What IMNM Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Varegacestat (AL102) Desmoid Phase 2/3 · NCT04871282 Active not recruiting
Lutetium Lu 177-labeled FAP-targeting Ligand… Solid Malignancies Phase 1 · NCT07505771 Recruiting
Anti-ROR1 Antibody-drug Conjugate IM-1021 Solid Malignancies Phase 1 · NCT06823167 Recruiting
IM-1340 Colorectal Cancer Phase 1 · NCT07890246 Not yet recruiting
IM-1617 Colorectal Cancer Phase 1 · NCT07578571 Recruiting
IMM-BCP-01 SARS-CoV2 Infection Phase 1 · NCT05429021 Terminated
Moxifloxacin Healthy Volunteer Phase 1 · NCT06855264 Completed
Varegacestat Reference Formulation Healthy Phase 1 · NCT07610005 Recruiting
Varegacestat Test Formulation A Healthy Phase 1 · NCT07610005 Recruiting
Varegacestat Test Formulation B Healthy Phase 1 · NCT07610005 Recruiting
Varegacestat Test Formulation C Healthy Phase 1 · NCT07610005 Recruiting

Also used in these trials (approved or third-party drugs, not IMNM's own candidates): Itraconazole.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IMNM holds $461.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $61.2M/quarter from operations, an estimated runway of 22.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 45 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMNM files for a raise →

👥 Who Owns IMNM

Insiders 1.4% Other 5%+ holders 4% Institutions (296 holders) 94.6% Public and other holders 0%
HolderTypeShares% of sharesAs of
T. Rowe Price Investment Management, Inc Institution (13G, 5%+) 19,676,883 16.67% 2026-06-30
Wellington Management Group LLP Institution (13G, 5%+) 6,041,333 5.12% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 5,725,578 4.85% 2026-09-30
Immunome Aggregator, LP 5%+ holder (13D) 4,768,583 4.04% 2025-01-31
Clay B Siegall
President and CEO, Director · +360,000 options
Insider 870,704 0.74% 2026-07-23
Philip Wagenheim
Director · +9,897 options
Insider 341,147 0.29% 2026-03-20
Max Rosett
Chief Financial Officer · +361,500 options
Insider 101,287 0.09% 2026-07-23
Isaac Barchas
Director · +9,897 options
Insider 92,211 0.08% 2026-08-10
Philip Tsai
Chief Technical Officer · +266,500 options
Insider 81,550 0.07% 2026-07-23
Robert Lechleider
Chief Medical Officer · +398,000 options
Insider 69,805 0.06% 2026-07-23
Jack Higgins
Chief Scientific Officer · +362,180 options
Insider 59,250 0.05% 2026-09-11
Sandra G. Stoneman
CHIEF LEGAL OFFICER & GC · +76,500 options
Insider 43,805 0.04% 2026-07-23

Share count 118,072,943 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full IMNM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMNM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.